Oncogene · 2020 · 74 citations · 33 references
MedicineCancer BiologyOncologyMetastasisMolecular OncologySignal TransductionCancer Cell SignalingCancer ProgressionColorectal CancerEpithelial-mesenchymal TransitionOncogenic Signaling PathwaysSignal Transduction In CancerBranched-chain Amino Acid MetabolismBranched-chain Amino AcidsCancer Cell MigrationEpithelial-mesenchymal Transition In CancerEpithelial-mesenchymal Transition MarkersErk SignalingPhosphoproteomicsRaf-mek-erk Signaling
Branched-chain α-keto acid dehydrogenase kinase (BCKDK), the key enzyme of branched-chain amino acids (BCAAs) metabolism, has been reported to promote colorectal cancer (CRC) tumorigenesis by upregulating the MEK-ERK signaling pathway. However, the profile of BCKDK in metastatic colorectal cancer (mCRC) remains unknown. Here, we report a novel role of BCKDK in mCRC. BCKDK is upregulated in CRC tissues. Increased BCKDK expression was associated with metastasis and poor clinical prognosis in CRC patients. Knockdown of BCKDK decreased CRC cell migration and invasion ex vivo, and lung metastasis in vivo. BCKDK promoted the epithelial mesenchymal transition (EMT) program, by decreasing the expression of E-cadherin, epithelial marker, and increasing the expression of N-cadherin and Vimentin, which are mesenchymal markers. Moreover, BCKDK-knockdown experiments in combination with phosphoproteomics analysis revealed the potent role of BCKDK in modulating multiple signal transduction pathways, including EMT and metastasis. Src phosphorylated BCKDK at the tyrosine 246 (Y246) site in vitro and ex vivo. Knockdown and knockout of Src downregulated the phosphorylation of BCKDK. Importantly, phosphorylation of BCKDK by Src enhanced the activity and stability of BCKDK, thereby promoting the migration, invasion, and EMT of CRC cells. In summary, the identification of BCKDK as a novel prometastatic factor in human CRC will be beneficial for further diagnostic biomarker studies and suggests novel targeting opportunities.
33
<i>IDH1</i>and<i>IDH2</i>Mutations in Gliomas
Hai Yan, D. Williams Parsons, Genglin Jin et al. · New England Journal of Medicine · 2009 · 5.9K citations · Full text
Metabolite profiles and the risk of developing diabetes
Thomas J. Wang, Martin G. Larson, Ramachandran S. Vasan et al. · Nature Medicine · 2011 · 3.1K citations · Full text
Joseph H. Taube, Jason I. Herschkowitz, Kakajan Komurov et al. · Proceedings of the National Academy of Sciences · 2010 · 1K citations · Full text
Pyruvate kinase M2 is a phosphotyrosine-binding protein
Heather R. Christofk, Matthew G. Vander Heiden, Ning Wu et al. · Nature · 2008 · 1K citations